UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2018

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________to__________

 

Commission File Number: 000-52545

 

WIZE PHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Delaware		88-0445167
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

24 Hanagar Street, Hod Hasharon, Israel		4527708
(Address of principal executive offices)		(Zip Code)

 

+(972) (72) 260-0536

(Registrant’s telephone number, including area code )

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes ☒    No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒    

 

The number of shares outstanding of the Registrant’s Common Stock, $0.001 par value, on November 13, 2018 was 8,462,550.

 

 

  

TABLE OF CONTENTS

 

		Page
PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36
Item 4.	Controls and Procedures	36
PART II - OTHER INFORMATION
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 6.	Exhibits	37
SIGNATURES		38

 

Throughout this report, unless otherwise designated, the terms “we,” “us,” “our,” the “Company,” “Wize” and “our company” refer to Wize Pharma, Inc. (formerly known as OphthaliX, Inc.), a Delaware corporation, and its wholly-owned Israeli subsidiary, Wize Pharma Ltd. (“Wize Israel”).

 

All dollar amounts refer to U.S. dollars unless otherwise indicated.

 

Unless derived from Wize’s financial statements or otherwise indicated, U.S. dollar translations of New Israeli Shekels (“NIS”) amounts presented in this report are translated using the rate of NIS 3.704 to one U.S. dollar, the exchange rate reported by the Bank of Israel for October 29, 2018.

 

On March 5, 2018, we effected a reverse stock split of our common stock, $0.001 par value (the “Common Stock”) at a ratio of one for twenty-four (1:24) (the “Reverse Stock Split”). Unless otherwise indicated, all share and per share amounts included in this Quarterly Report for all periods prior to March 5, 2018, have been adjusted retroactively to reflect the effects of the Reverse Stock Split.

 

  

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

WIZE PHARMA, INC.

 

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF September 30, 2018

 

U.S. DOLLARS IN THOUSANDS

 

UNAUDITED

 

INDEX

 

	Page
Consolidated Balance Sheets	2 - 3
Consolidated Statements of Comprehensive Loss	4
Consolidated Statements of Changes in Stockholders’ Deficit	5
Consolidated Statements of Cash Flows	6 - 7
Notes to Unaudited Interim Consolidated Financial Statements	8 - 25

 

- - - - - - - - - - - - - -

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

 

		As of September 30,				As of December 31,
		2018				2017
		Unaudited				Audited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	99			$	215
Restricted bank deposit			-				12
Marketable equity securities			34				323
Other current assets			147				40
Total current assets			280				590
NON-CURRENT ASSETS:
Property and equipment, net			6				5
TOTAL ASSETS		$	286			$	595

    

The accompanying notes are an integral part of the unaudited interim consolidated financial statements (the “Q3 2018 Financial Statements”).

       

   

WIZE PHARMA, INC. AND SUBSDIARIES

 

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share and per share data)

 

		As of September 30,				As of December 31,
		2018				2017
		Unaudited				Audited
LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES:
Trade payables		$	84			$	43
Other accounts payable			242				196
Current portion of license purchase obligation			250				250
Convertible loans, net			1,906				3,204
Total current liabilities			2,482				3,693
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT:
Preferred Stock, with $0.001 par value per share - Authorized: 1,000,000 shares at September 30, 2018 and December 31, 2017; Issued and outstanding: 0 at September 30, 2018 and December 31, 2017			-				-
Common Stock, with $0.001 par value per share - 500,000,000 shares authorized at September 30, 2018 and December 31, 2017; 5,362,550 and 4,350,608 shares issued and outstanding at September 30, 2018 and December 31, 2017			5				4
Additional paid- in capital			25,786				23,397
Accumulated other comprehensive loss			(73	)			(47	)
Accumulated deficit			(27,914	)			(26,452	)
Total Stockholders’ deficit			(2,196	)			(3,098	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT		$	286			$	595

   

The accompanying notes are an integral part of the Q3 2018 Financial Statements.

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands (except share and per share data)

 

		Nine months ended September 30,								Three months ended September 30,
		2018				2017				2018				2017
		Unaudited								Unaudited
Operating expenses:
Research and development expenses		$	(521	)		$	(288	)		$	(222	)		$	(107	)
General and administrative expenses			(2,244	)			(760	)			(738	)			(229	)
Operating loss			(2,765	)			(1,048	)			(960	)			(336	)
Financial income (expense), net			1,277				(1,016	)			445				(392	)
Net loss		$	(1,488	)		$	(2,064	)		$	(515	)		$	(728	)
Other comprehensive loss:
Foreign currency translation adjustments			-				(51	)			-				30
Other comprehensive loss			-				(51	)			-				30
Comprehensive loss		$	(1,488	)		$	(2,115	)		$	(515	)		$	(698	)
Basic and diluted net loss per share		$	(0.30	)		$	(0.64	)		$	(0.10	)		$	(0.2	)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share			4,928,903				3,208,948				5,327,743				3,578,987

   

The accompanying notes are an integral part of the Q3 2018 Financial Statements.

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

U.S. dollars in thousands (except share data)

 

		Ordinary Shares								Additional paid-in				Treasury				Receipt on account of stock to be				Accumulated other comprehensive				Accumulated				Total stockholders’
		Number				Amount				capital				shares				issued				income (loss)				deficit				deficit
Balance as of January 1, 2017 (audited)			3,023,043			$	3			$	23,391			$	(747	)			-			$	5			$	(23,483	)		$	(831	)
Beneficial conversion feature in respect to convertible loan			-				-				811				-				-				-				-				811
Classification of derivative liability for right to future investment into equity			-				-				280				-				-				-				-				280
Issuance of units consisting of common stock and detachable warrants, net of issuance costs			860,987				1				965				-				-				-				-				966
Exercise of options into common stock			31,439				-	*)			21				-				-				-				-				21
Cancellation of treasury shares with respect to reverse recapitalization			-				-				(747	)			747				-				-				-				-
Shares issued with respect to reverse recapitalization			435,139				-	*)			298				-				-				-				-				298
Amount that was allocated to the repurchase of beneficial conversion feature in convertible loans			-				-				(2,800	)			-				-				-				-				(2,800	)
Amount that was allocated to the right for future investment - loan 2016			-				-				44				-				-				-				-				44
Amount that was allocated to the right for future investment- loan 2017			-				-				1,115				-				-				-				-				1,115
Deemed dividend with respect to the repurchase of  right for future investment			-				-				-				-				-				-				(3	)			(3	)
Stock-based compensation			-				-				19				-				-				-				-				19
Foreign currency translation adjustment			-				-				-				-				-				(78	)			-				(78	)
Changes in unrealized gains on marketable equity securities			-				-				-				-				-				26								26
Net loss for the year			-				-				-				-				-				-				(2,966	)			(2,966	)
Balance as of December 31, 2017 (audited)			4,350,608				4				23,397				-				-				(47	)			(26,452	)			(3,098	)
Cumulative effect adjustment as a result from transition to ASU 2016-01 (see note 2b)			-				-				-				-				-				(26	)			26				-
Issuance of shares with respect to exercise of PIPE Warrants and right for future investment (see note 6d)			788,658				1				1,144				-				-				-				-				1,145
Stock-based compensation			223,284				-	*)			1,245				-				-				-				-				1,245
Net loss for the interim period			-				-				-				-				-				-				(1,488	)			(1,488	)
Balance as of September 30, 2018 (unaudited)			5,362,550			$	5			$	25,786			$	-			$	-			$	(73	)		$	(27,914	)		$	(2,196	)

 

*)

Representing amount less than $1

 

The accompanying notes are an integral part of the Q3 2018 Financial Statements.

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

 

		Nine months ended September 30,
		2018				2017
		Unaudited
Cash flows from operating activities
Net loss		$	(1,488	)		$	(2,064	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation			1				*	)
Stock-based compensation			1,245				33
Change in fair value of marketable equity securities			32				-
Amortization of discounts resulting from beneficial conversion feature and derivative liability and debt issuance costs related to convertible loans			-				729
Accrued interest on convertible loans			40				33
Amortization of premium related to convertible loans			(1,338	)			-
Change in the fair value of derivative liability for Right to Future Investment			-				246
Increase in license purchase obligation			150				-
Change in the fair value of license purchase obligation			-				1
Change in:
Other current assets			(100	)			(28	)
Account receivables			(7	)			-
Trade payables			41				30
Other accounts payable			46				37
Net cash used in operating activities			(1,378	)			(983	)
Cash flows from investing activities
Purchase of property and equipment			(2	)			(2	)
Proceeds from sale of marketable equity securities			257				-
Restricted bank deposit			12				-
Net cash provided by (used in) investing activities			267				(2	)
Cash flows from financing activities
Proceeds from loans from controlling shareholder			-				82
Proceeds from issuance of convertible loan, net of issuance costs			-				620
Payment of license purchase obligation			(150	)			(154	)
Proceeds from issuance of shares with respect to exercise of PIPE Warrants and right for future investment			1,145				-
Proceeds from issuance of units consisting of ordinary shares and detachable warrants, net of issuance costs			-				963
Net cash provided by financing activities			995				1,511
Foreign currency translation adjustments on cash and cash equivalents			-				18
Increase in cash and cash equivalents			(116	)			544
Cash and cash equivalents at the beginning of the period			215				28
Cash and cash equivalents at the end of the period		$	99			$	572

 

*)

Representing an amount of less than $1

 

(Continued)

  

 

WIZE PHARMA, INC. AND SUBSDIARIES

   

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

 

(Continued)

 

		Nine months ended September 30,
		2018				2017
		Unaudited
Supplemental disclosure of non-cash financing activities:
Reclassification of derivative liability for Right to Future Investment into equity		$	-			$	280
Conversion of bridge loans from controlling shareholder to convertible loans		$	-			$	206

  

The accompanying notes are an integral part of the Q3 2018 Financial Statements.

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 1:-

GENERAL

 

a.

Wize Pharma, Inc. (formerly: OphthaliX Inc.) (the “Company” or “Wize”) was incorporated in the State of Delaware.

 

On November 16, 2017, the Company completed the acquisition of Wize Pharma Ltd., an Israeli company (“Wize Israel”) by way of a reverse triangular merger.

 

Wize Israel is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (“DES”).

 

Commencing August 30, 2016, Wize Israel manages most of its activity through OcuWize Ltd., a wholly-owned Israeli Subsidiary which manages and develops most of the Company’s activity under the License Agreement.

 

In May 2015, Wize Israel entered into an Exclusive Distribution and Licensing Agreement (as amended, the “License Agreement”) with Resdevco Ltd. (“Resdevco”), whereby Resdevco granted to Wize Israel an exclusive license to purchase, market, sell and distribute a formula known as LO2A (“LO2A”) in the United States, Israel, Ukraine and China as well as a contingent right to do the same in other countries. LO2A is a drug developed for the treatment of DES, and other ophthalmological illnesses, including Conjunctivochalasis (“CCH”) and Sjögren’s syndrome (“Sjögren’s”). Pursuant to the LO2A License Agreement, Wize Israel is required to pay Resdevco certain royalties for sales in the licensed territories based on an agreed-upon price per unit of either $0.60, in the United States, Israel and Ukraine, or in the low single digits of US Dollars, in the People’s Republic of China, payable on a semi-annual basis, subject to making certain minimum royalty payments as set forth in the LO2A License Agreement. In July 2018, the Company paid Resdevco royalties in the amount of $150.

 

Following the Merger (as defined below) transaction as described in Note 1d, the business of Wize Israel became the ongoing business of the Company and the Company is defined as a “smaller reporting company”, according to Item 10(f)(1) of Regulation S-K, as promulgated by the United States Securities and Exchange Commission (the “SEC”).

 

See Note 8 below with respect to the private placement of the Company which closed in October 2018.

 

b.

Going concern uncertainty and management plans:

 

The Company has not yet generated any revenues from its current operations other than immaterial revenue in Israel during the third quarter of 2018 of $7 which were deducted from research and development expenses, and therefore is dependent upon external sources for financing its operations. As of September 30, 2018, the Company has an accumulated deficit of $27,914 and a stockholders’ deficit of $2,196.

 

In addition, in the three and nine month periods ended September 30, 2018, and in the year ended December 31, 2017, the Company reported losses and negative cash flows from operating activities.  Management considered the significance of such conditions in relation to the Company’s ability to meet its current and future obligations and determined that such conditions raise substantial doubt about the Company’s ability to continue as a going concern.  

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 1:-

GENERAL (Cont.)

 

The accompanying Q3 2018 Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

Until such time as the Company generates sufficient revenue to fund its operations (if ever), the Company plans to finance its operations through the sale of equity or equity-linked securities and/or debt securities and, to the extent available, short-term and long-term loans. There can be no assurance that the Company will succeed in obtaining the necessary financing to continue its operations as a going concern.

 

c.

Risk factors:

 

As of September 30, 2018, the Company had an accumulated deficit of $27,914. The Company has historically incurred net losses and is not able to determine whether or when it will become profitable, if ever. To date, the Company has not commercialized any products or generated any revenues from product sales other than immaterial revenue in Israel during the third quarter of 2018 of $7 which were deducted from research and development expenses and accordingly it does not have a revenue stream to support its cost structure. The Company’s losses have resulted principally from costs incurred in development and discovery activities.

 

The Company expects to continue to incur losses for the foreseeable future, and these losses will likely increase as it:

 

●

initiates and manages pre-clinical development and clinical trials for LO2A;

●

seeks regulatory approvals for LO2A;

●

implements internal systems and infrastructures;

●

seeks to license additional technologies to develop;

●

pays royalties related to the License Agreement;

●

hires management and other personnel; and

●

moves towards commercialization.

 

No certainty exists that the Company will be able to complete the development of LO2A for CCH, Sjögren’s or any other ophthalmic disorder, due to financial, technological or other difficulties. If LO2A fails in clinical trials or does not gain regulatory clearance or approval, or if LO2A does not achieve market acceptance, the Company may never become profitable. Even if the Company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis.

  

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 1:-

GENERAL (Cont.)

 

The Company’s inability to achieve and then maintain profitability would negatively affect its business, financial condition, results of operations and cash flows.

 

Moreover, the Company’s prospects must be considered in light of the risks and uncertainties encountered by an early-stage company and in highly regulated and competitive markets, such as the biopharmaceutical market, where regulatory approval and market acceptance of its products are uncertain. There can be no assurance that the Company’s efforts will ultimately be successful or result in revenues or profits.

 

d.

Merger transaction:

 

On May 21, 2017, the Company and a wholly-owned private Israeli subsidiary of the Company, Bufiduck Ltd. (“Merger Sub”), and Wize Israel, entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other things, Merger Sub merged with and into Wize Israel, with Wize Israel becoming a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the “Merger”). On November 16, 2017, the Merger was closed (the “Closing Date”).

 

On the Closing Date, each issued and outstanding ordinary share of Wize Israel was automatically converted into  4.1445791236989 shares (the “Exchange Ratio”) (such number not being converted as per the Reverse Stock Split described in Note 6b) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). As a result, an aggregate of 3,915,469 shares, or 90% of the issued and outstanding Common Stock were issued to Wize Israel’s shareholders. The pre-Merger stockholders of the Company retained an aggregate of 435,052 shares, or 10% of the issued and outstanding Common Stock.

 

Wize Israel’s ordinary shares were delisted from the Tel Aviv Stock Exchange and there is no longer a public trading market for Wize Israel’s ordinary shares in Israel.

 

The Merger between the Company and Wize Israel became effective on November 16, 2017, and following such Merger, Wize Israel activities are the sole activities of the Company. The Common Stock is currently quoted on the OTCQB under the symbol “WIZP.”

 

The Merger was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, was considered a non-operating public shell, and is therefore not a business as defined in ASC 805. Under reverse capitalization accounting, Wize Israel was considered the acquirer for accounting and financial reporting purposes. The Merger was accounted for in a manner that is substantially the same as a reverse acquisition under ASC 805, except that any excess fair value of the consideration transferred over the net fair value of the monetary assets of the Company was recognized as a reduction of equity.

  

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 1:-

GENERAL (Cont.)

 

The Financial Statements reflect the operations of the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former stockholders of the legal acquirer and a recapitalization at the equity of the accounting acquirer.

 

The interim consolidated financial statements include the accounts of the Company since the Closing Date and the accounts of Wize Israel since its inception. See Note 3 for discussion of the basis of presentation for the Financial Statements.

  

NOTE 2:-

SIGNIFICANT ACCOUNTING POLICIES

 

The Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).

 

a.

Use of estimates in preparation of the Financial Statements:

 

The preparation of the Financial Statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the Financial Statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made.

 

These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the Financial Statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.

 

As applicable to the consolidated financial statements, the most significant estimates and assumptions relate to the going concern assumptions and determining the fair value of embedded and freestanding financial instruments related to convertible loans and to stock- based compensation.

 

The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2017 are applied consistently in these Financial Statements, except as described in b below.

 

b.

Recently Issued Accounting Pronouncements

 

ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”

 

Commencing January 1, 2018 the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”).

 

ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.

 

An entity should apply the amendments in ASU 2014-09 using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.

 

In accordance with an amendment to ASU 2014-09, the new guidance is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company).

 

Since the company did not report significant revenues, the adoption of ASU 2014-09 did not have a significant impact on its consolidated financial statements.

 

ASU 2016-01, “Financial Instruments—Overall (Topic 825-10): “Recognition and Measurement of Financial Assets and Financial Liabilities.”

 

Commencing January 2018, the Company applied ASU 2016-01, “Financial Instruments—Overall (Topic 825-10): “Recognition and Measurement of Financial Assets and Financial Liabilities.” (ASU 2016-01).

 

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 2:-

SIGNIFICANT ACCOUNTING POLICIES (Cont.)

 

ASU 2016-01 amends the guidance on the classification and measurement of financial instruments. Among others, ASU 2016-01 requires that equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) will be measured at fair value with changes in fair value recognized in net income. Also, ASU 2016-01, simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment and requires a public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes.

 

ASU 2016-01, requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure a liability at fair value in accordance with the fair value option for financial instruments. ASU 2016-01 also requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or in the accompanying notes to the financial statements.

 

For public business entities, the amendments of ASU 2016-01 became effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.

 

ASU 2016-01 requires that its amendment will be applied using a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. However, the amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption of the Update.

 

Following the adoption of ASU 2016-01, the Company reclassified unrealized gains and losses amounts related to its investment in marketable equity securities that previously were classified as available-for-sale securities from accumulated other comprehensive income to accumulated deficit. Following the adoption, such investment is accounted for at fair value and the changes in fair value are recognized in net income or loss.

 

Accounting Standard Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting

 

In June 2018, the FASB issued Accounting Standard Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (ASU 2018-07). ASU 2018-07 aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions.

 

Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards within the scope of Topic 718 will be measured at grant-date fair value of the equity instruments that an entity is obligated to issue when the goods has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied.

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 2:-

SIGNIFICANT ACCOUNTING POLICIES (Cont.)

 

Equity-classified nonemployee share-based payment awards will be measured at the grant date (the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award). With respect to awards with performance conditions, ASU 2018-07 concludes that, consistent with the accounting for employee share-based payment awards, an entity will consider the probability of satisfying performance conditions when nonemployee share-based payment awards contain such conditions.

 

ASU 2018-07 also requires that the classification of equity classified nonemployee share-based payment awards will continue to be subject to the requirements of Topic 718 unless the award was modified after the goods has been delivered, the service has been rendered, any other conditions necessary to earn the right to benefit from the instruments have been satisfied, and the nonemployee is no longer providing goods or services. This eliminates the requirement to reassess classification of such awards upon vesting.

 

In addition, ASU 2018-07 includes certain non-public entity-specific amendments.

 

ASU 2018-07 is effective for public entities in annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted, including in an interim period, but not before an entity adopts the new revenue recognition guidance (which became effective for the Company and adopted with no significant effect, in its interim financial statements for 2018).

 

An entity should only remeasure liability-classified awards that have not been settled by the date of adoption and equity-classified awards for which a measurement date has not been established, through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, the entity is required to measure these nonemployee awards at fair value as of the adoption date.

 

The Company has elected to early apply ASU 2018-07 in its interim financial statements for the interim period ended September 2018. However, as there are no liability-classified awards and as there were no equity-classified awards for which a measurement date has not been established as of January 1, 2018 (the beginning of the fiscal year of adoption), the adoption did not have significant effect on the financial statements. Also, as a result of the adoption all equity-classified nonemployee share-based payment awards granted during 2018 were measured at grant-date fair value of the equity instruments that the Company is obligated to issue.

  

NOTE 3:-

UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

The accompanying Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information, and as discussed in Note 1d, include the accounts of Wize Israel since its inception, and the accounts of the Company since the Closing Date. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 3:-

UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

 

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or for any other interim period.

 

The accompanying Financial Statements and related notes should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the SEC on March 29, 2018 and amended on June 5, 2018. The accompanying consolidated balance sheet as of December 31, 2017, and the accompanying consolidated statements of changes in stockholders’ deficit for the year then ended has been derived from those audited financial statements.

  

NOTE 4:-

CONTINGENT LIABILITIES AND COMMITMENTS

 

On March 28, 2018, the Company signed an agreement to rent an office from an unrelated third party. The rental period is two years from April 1, 2018, with an option for additional one year. The rental fees amounted to $1 per month plus participation in office usage expenses.

 

The Company has additional commitments, as described in note 11b to the Company’s consolidated financial statements and related notes for the fiscal year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the SEC on March 29, 2018 and amended on June 5, 2018.

 

NOTE 5:-

CONVERTIBLE LOANS

 

On March 20, 2016, Wize Israel entered into an agreement (as amended on March 30, 2016, the “2016 Loan Agreement”) pursuant to which Rimon Gold Assets Ltd. (“Rimon Gold”) extended a loan in the principal amount of up to NIS 2 million (approximately $531 according to an exchange rate on March 20, 2016, the loan origination date), which bears interest at an annual rate of 4% (the “2016 Loan”). Pursuant to the 2016 Loan Agreement, as modified by the 2017 Loan Agreement (as defined below) and the 2017 Loan Amendment (as defined below), the 2016 Loan had a maturity date of December 31, 2018. See Note 8 with respect to the modification of the maturity date of the 2016 Loan subsequent to September 30, 2018.

 

Under the 2016 Loan Agreement, Rimon Gold had the right, at its sole discretion, to convert any outstanding portion of the 2016 Loan, but not less than NIS 100,000 (approximately $26 according to an exchange rate on March 20, 2016, the loan origination date), into Wize Israel ordinary shares at a conversion price per share of NIS 15.2592 (approximately $3.84), subject to adjustments for stock splits and similar events set forth in the 2016 Loan Agreement. As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016 Loan was adjusted to NIS 3.6 (approximately $0.96). As a result of the 2017 Loan Amendment (as defined below), the aggregate principal amount of the 2016 Loan is $531 and the conversion price per share for the 2016 Loan was adjusted to $0.9768.

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 5:-

CONVERTIBLE LOANS (Cont.)

 

In addition, under the 2016 Loan Agreement, as modified by the 2017 Loan Agreement (as defined below) and the 2017 Loan Amendment (as defined below), Rimon Gold has the right (the “2016 Investment Right”), until June 30, 2019, to invest up to $797 , in the aggregate, at an agreed price per share, which was adjusted based on the Exchange Ratio from NIS 20.4 (approximately $6.00) to NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment (as defined below), from NIS 5.04 to $1.308 (subject to adjustments in case of stock splits or similar events). See Note 8 with respect to the modification of the maturity date of the 2016 loan subsequent to September 30, 2018.

 

On January 15, 2017, Wize Israel entered into the loan agreement (the “2017 Loan Agreement”) with Ridge Valley Corporation (“Ridge”), and, by way of entering into assignments and assumption agreements following such date, also with Rimon Gold and Shimshon Fisher (“Fisher,” and together with Ridge and Rimon Gold, the “2017 Lenders”), whereby each of the lenders extended a loan in the principal amount of up to NIS 1 million (approximately $274 according to an exchange rate on January 17, 2017, the loan origination date) and in the aggregate principal amount of up to NIS 3 million (approximately $822 according to an exchange rate on January 17, 2017, the loan origination date), which bears interest at an annual rate of 4% (the “2017 Loan”, and together with the 2016 Loan, the “Loans”). Pursuant to the 2017 Loan Agreement and the 2017 Loan Amendment (as defined below), the 2017 Loan has a maturity date of December 31, 2018. See Note 8 with respect to the modification of the maturity date of the 2016 loan subsequent to September 30, 2018.

 

Under the 2017 Loan Agreement, each of the 2017 Lenders had the right, at its sole discretion, to convert any outstanding portion of the 2017 Loan, but no less than NIS 100,000 (approximately $28 according to an exchange rate on January 17, 2017, the loan origination date), that the lender provided to Wize Israel (each such portion converted into Wize Israel ordinary shares at a conversion price per share equal to the lower of (1) NIS 24 (approximately $6.72) and (2) the lowest price per share of Wize Israel in any offering made by Wize Israel following the date of the 2017 Loan Agreement and through the date of such requested conversion, subject to adjustments for stock splits and similar events set forth in the 2017 Loan Agreement (the “2017 Loan Conversion Price”). As a result of the 2017 PIPE, the 2017 Loan Conversion Price for Rimon Gold, Fisher and Ridge was adjusted to NIS 16.8 (approximately $4.80), and as a result of the Merger, the 2017 Loan Conversion Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately $1.15). As a result of the 2017 Loan Amendment (as defined below), the aggregate principal amount of the 2017 Loan is $822 and the 2017 Loan Conversion Price was adjusted to $1.1112. See “2017 Loan Amendment” below.

 

In addition, under the 2017 Loan Agreement, as modified by the 2017 Loan Amendment (as defined below), the 2017 Lenders have the right (the “2017 Investment Right”), until June 30, 2019, to invest up to $1,233, in the aggregate, at an agreed price per share equal to 120% of the applicable 2017 Loan Conversion Price, which was adjusted in December 2017, based on the 2017 Loan Amendment, to a fixed exercise price of $1.332 (subject to adjustments in case of stock splits or similar events). See Note 8 with respect to the modification of the maturity date of the 2016 loan subsequent to September 30, 2018.   

   

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 5:-

CONVERTIBLE LOANS (Cont.)

 

On December 21, 2017, the Company entered into an amendment (the “2017 Loan Amendment”) to the 2016 Loan Agreement and the 2017 Loan Agreement. Pursuant to the 2017 Loan Amendment, (i) the maturity date of the Loans was extended from December 31, 2017 to December 31, 2018; (ii) the exercise period of the 2016 Investment Right was amended so that it shall expire on June 30, 2019; (iii) the exercise period of the 2017 Investment Right was amended so that it shall expire, without the need to first convert the 2017 Loan, on June 30, 2019; and (iv) the below terms of the Loans were amended to be denominated in U.S. dollars instead of NIS:

 

			2017 Loan				2016 Loan
	Aggregate principal amount		$	822	(*)		$	531
	Conversion price per Company’s share		$	1.1112			$	0.9768
	Aggregate maximum of Right to Future Investment		$	1,233	(**)		$	797
	Exercise Price of Right to Future Investment		$	1.332			$	1.308

 

(*)

Principal loan amount of $274 for each of the three 2017 Lenders.

(**)

Maximum of Right to Future Investment of $411 for each of the three 2017 Lenders.

 

The below table describes the roll forward of 2017 Loan and 2016 Loan for the nine months ended September 30, 2018 and the year ended December 31, 2017:

 

			September 30,				December 31,
			2018				2017
	Opening balance		$	3,204			$	289
	Proceeds from issuance of convertible loan, net of issuance cost			-				811
	Recognition of BCF as a discount of 2017 Loan			-				(811	)
	Amortization of premium related to convertible loans			(1,338	)(*)			-
	Amortization of discounts resulting from BCF and derivative liability and debt issuance costs related to 2017 Loan and 2016 Loan			-				1,122
	Accrued interest on 2017 Loan and 2016 Loan			40				47
	Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishment			-				(1,458	)
	Amount allocated to 2016 and 2017 Loan based on modified terms			-				3,204
			$	1,906			$	3,204

    

(*)

The amortization of premium represents the periodic amortization of the balance of the amount that was allocated to the 2016 and 2017 Loans upon the 2017 Loan amendment into the respective principal amount of such loans.

 

See Note 8 with respect to the modifications to the convertible loan agreements subsequent to September 30, 2018. 

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

    

NOTE 6:-

STOCKHOLDERS’ DEFICIT

 

a.

The Common Stock confers upon their holders the right to participate and vote in general shareholder meetings of the Company and to share in the distribution of dividends, if any, declared by the Company, and rights to receive a distribution of assets upon liquidation.

 

b.

On December 11, 2017, the Company announced a notice of special meeting of stockholders, according to which, a special meeting of the stockholders was held on February 19, 2018, for the purpose of considering to grant the Company’s Board of Directors the authority, in its sole direction, to approve an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of not less than 1-for-10 and not more than 1-for-200.

 

c.

On February 19, 2018, the stockholders of the Company approved a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of not less than 1-for-10 and not more than 1-for-200 at any time prior to February 19, 2019, with such ratio to be determined by the Company’s Board of Directors, in its sole discretion. On February 22, 2018, the Company’s Board of Directors approved a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of 1-for-24 (“Reverse Stock Split”).

 

For accounting purposes, all share and per share amounts for Common Stock, warrants stock, options stock and loss per share amounts have been adjusted to give retroactive effect to the Reverse Stock Split (see also Note 1d) for all periods presented in these Financial Statements. Any fractional shares that resulted from the Reverse Stock Split have been rounded up to the nearest whole share.

 

d.

On February 28, 2018, the Company received notices from existing stockholders and lenders to exercise 2016 Investment Right and 2017 Investment Rights and warrants issued in a private placement of Wize Israel that was completed in July and August 2017 (the “PIPE Warrants”) to purchase an aggregate of 788,658 shares of Common Stock. During the nine months ended September 30, 2018, the Company received the aggregate exercise price of approximately $1,148 and issued 788,658 shares of Common Stock as follows:

 

1.

144,168 PIPE Warrants were exercised into 144,168 shares of common stock by certain stockholder. The aggregate exercise price amounted to approximately $293 was received in cash. As of September 30, 2018, 759,869 PIPE Warrants remain outstanding.

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 6:-

STOCKHOLDERS’ DEFICIT (Cont.)

 

2.

Certain holders of 2016 Investment Rights and 2017 Investment Rights exercised a portion of such rights and invested, in the aggregate, $854 for 217,442 and 427,048 respectively, shares of Common stock at an exercise price per share of $1.308 and $1.332 per share, respectively. As of September 30, 2018, the remaining 2016 Investment Rights and 2017 Investment Rights amount to approximately $765.

 

e.

In April and June 2018, the Company issued 24,306 shares of Common Stock to two of its service providers in exchange for their services provided in 2018. The Company recognized an amount of $110 in its interim financial statements for the nine month period ended September 30, 2018 and an amount of approximately $15 will be recognized until the end of 2018.

 

f.

On May 10, 2018, the Company filed an amendment to the S-1 Registration Statement, for the purpose of registering (i) 922,330 shares of Common Stock that were outstanding as of that date; and (ii) 338,945 shares of Common Stock which are issuable upon conversion of the 2016 Loan and/or the 2017 Loan. The S-1 Registration Statement was declared effective by the SEC on July 12, 2018.

 

g.

In July 2018, the Company issued 67,778 shares of Common Stock to certain service providers in exchange for their services provided in 2018. The Company recognized an amount of $381 in its interim financial statements for the nine month period ended September 30, 2018.

 

h.

Stock-based compensation:

 

The 2012 Plan

 

In 2012, the Company’s Board of Directors approved the adoption of the 2012 Stock Incentive Plan (the “2012 Plan”).

 

An Israeli annex was subsequently adopted in 2013 to comply with the requirements set by the Israeli law in general and in particular with the provisions of section 102 of the Israeli tax ordinance. Under the 2012 Plan and Israeli annex, the Company may grant its officers, directors, employees and consultants, stock options, restricted stocks and Restricted Stock Units (“RSUs”) of the Company. Each Stock option granted shall be exercisable at such times and terms and conditions as the Company’s Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years. Upon the adoption of the 2012 Plan, the Company reserved for issuance 45,370 shares of Common Stock, $0.001 par value each.

 

As of September 30, 2018, the Company has 40,474 shares of Common Stock available for future grant under the 2012 Plan. As of September 30, 2018, under the 2012 Plan, the Company had options exercisable into 4,896 shares of Common Stock outstanding and exercisable.

    

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 6:-

STOCKHOLDERS’ DEFICIT (Cont.)

 

The 2018 Plan

 

On February 22, 2018, the Company’s Board of Directors approved the adoption of the 2018 Stock Incentive Plan (the “2018 Plan”), including an Israeli annex to comply with Israeli law, in particular the provisions of section 102 of the Israeli Income Tax Ordinance.

 

Under the 2018 Plan, the Company may grant its employees, directors, consultants and/or contractors’ stock options, shares of Common Stock, restricted stock and restricted stock units of the Company. The Compensation Committee of the Board of Directors is currently serving as the administrator of the 2018 Plan. Each stock option granted is exercisable, unless otherwise determined by the administrator, in twelve equal installments over the three - year period from the date of grant. Unless otherwise determined by the administrator, the term of each award will be seven years.

 

The exercise price per share subject to each option will be determined by the administrator, subject to applicable laws and to guidelines adopted by the Board of Directors from time to time. In the event the exercise price is not determined by the administrator, the exercise price of an option will be equal to the closing stock price of the Common Stock on the last trading day prior to the date of grant. Upon the adoption of the 2018 Plan, the Company’s Board of Directors reserved for issuance 2,500,000 shares of Common Stock. Through September 30, 2018, the Company granted 255,000 options to directors, officers and a consultant see also Note 6k and Note 6l.

 

i.

On March 1, 2018, the Company filed a certificate of amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware in order to effectuate the Reverse Stock Split (see also Note 6b).

 

j.

On April 4, 2018, the Company granted to its officers, directors and a consultant, 131,200 fully vested RSUs. The Company determined the fair value of the RSUs to be the quoted market price of the Company’s common stock units on the date of issuance. The aggregate fair value of these restricted stock units issued was $471, and was recognized during the three month period ended June 30, 2018.

 

k.

On April 4, 2018, the Company granted to its officers, directors and a consultant options exercisable into 229,500 shares of Common Stock and have exercise price of $3.59 per stock. The options will vest quarterly over a period of 36 months. The Company recognized $260 during the nine months period ended September 30, 2018.

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 6:-

STOCKHOLDERS’ DEFICIT (Cont.)

 

l.

On August 15, 2018, the Company granted to its consultant options exercisable into 25,500 shares of Common Stock at an exercise price of $4.50 per share of Common stock. The options will vest quarterly over a period of 36 months.

 

Transactions related to the grant of fully vested RSUs to officers, directors and a consultant during the period ended September 30, 2018, were as follows:

 

			September 30,
			2018
	Opening balance			-
	Granted			131,200
	Outstanding as of September 30, 2018			131,200

 

Transactions related to the grant of options to employees and directors under the 2012 Plan during the period ended September 30, 2018, were as follows:

 

			As of September 30, 2018
			Number of options				Weighted average exercise price				Weighted average remaining contractual life (in years)
	Options outstanding as of December  31, 2017			4,896			$	190.8				4.86
	Granted			-				-				-
	Options outstanding and exercisable as of September 30, 2018			4,896			$	190.8				4.11

   

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 6:-

STOCKHOLDERS’ DEFICIT (Cont.)

 

Transactions related to the grant of options to employees and directors under the 2018 Plan during the period ended September 30, 2018, were as follows:

 

			As of September 30, 2018
			Number of options				Weighted average exercise price				Weighted average remaining contractual life (in years)
	Options outstanding as of December  31, 2017			-			$	-				-
	Granted			255,000			$	3.68				6.55
	Options outstanding as of September 30, 2018			255,000			$	3.68				6.55
	Options exercisable as of September 30, 2018			19,125			$	3.59				6.5

 

At September 30, 2018, there was $351 of total unrecognized compensation cost related to non-vested option grants that is expected to be recognized over a weighted-average period of 2.5 years. The intrinsic value of options outstanding and exercisable at September 30, 2018 was not significant.

 

The Company uses the Black-Scholes option-pricing model to estimate fair value of grants of stock options. With respect to grants of options, the risk-free rate of interest was based on the U.S. Treasury rates appropriate for the contractual term of the grant, expected volatility was calculated based on average volatility of the Company and five representative companies and expected term of stock-based grants of 3.63-5 years.

    

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 7:-

FINANCIAL INCOME (EXPENSE), NET

 

Composition:

 

			Nine months ended September 30,								Three months ended September 30,
			2018				2017				2018				2017
	Financial income:
	Exchange rate differences		$	15			$	-			$	18			$	-
	Amortization of premium related to convertible loans			1,338				-				446				-
	Total finance income			1,353				-				464				-
	Financial expenses:
	Accrued interest on convertible loans			(40	)			(33	)			(13	)			(14	)
	Amortization of BCF, proceeds allocated to the derivative liability and debt issuance costs for convertible loans			-				(729	)			-				(368	)
	Change in the fair value of derivative liability for Right to Future Investment			-				(246	)			-				-
	Amortization of discount and exchange rate differences on license purchase obligation			-				(1	)			-				(5	)
	Change in fair value of marketable equity securities			(32	)			-				(4	)			-
	Bank commissions			(4	)			(7	)			(2	)			(5	)
	Total financial expenses			(76	)			(1,016	)			(19	)			(392	)
	Total financial income (expense), net		$	1,277			$	(1,016	)		$	445			$	(392	)

     

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 8:-

SUBSEQUENT EVENTS

 

On October 22, 2018, The Company entered into a securities purchase agreement (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company agreed to sell to the investors, and the investors agreed to purchase from the Company, in a private placement, an aggregate of (i) 3,100,000 shares of common stock, for a purchase price of $1.00 per share, and (ii) 1,350 shares of newly created Series A Preferred Stock (each convertible into 1,000 shares of common stock), for a purchase price of $1,000 per share, for aggregate gross proceeds under the Purchase Agreement of $4,450. The Company also agreed to issue to the investors Series A warrants (the “Series A Warrants”) to purchase an aggregate of 4,450,000 shares of common stock (equal to 100% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)), and Series B warrants (the “Series B Warrants, and together with the Series A Warrants, the “Warrants”), to purchase an aggregate of 4,450,000 shares of common stock (equal to 100% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)). The Series A Warrants will have an exercise price of $1.10 per share, and the Series B Warrants will have an exercise price of $1.00 per share. The investors under the Purchase Agreement include prior investors in the Company and a lender to the Company.

 

The Series A Warrants, when issued, will have a term of 5 years from issuance, and the Series B Warrants will have a term that expires 20 days following the later of (i) the public announcement of Phase II clinical data for LO2A and (ii) six months following the issuance date, provided that, for each day after the issuance date that an Equity Conditions Failure (as defined in the Series B Warrants) has occurred, the expiration date of the Series B Warrants will be extended by one day.

 

In the event that, during the period commencing upon execution of the Purchase Agreement, and expiring on the trading day immediately following the date that the Company has raised, beginning after the issuance date of the Warrants, at least $10 million in gross proceeds from the issuance of the Company’s securities, the Company issues or sells common stock (or securities convertible into or exercisable into common stock) at a purchase price (or conversion or exercise price, as applicable) lower than the exercise price of the Warrants, than the exercise price of the Warrants will be reduced to such lower price, subject to certain exceptions.

 

Pursuant to the Purchase Agreement, the Company granted to the investors thereunder, for a period of three years from the closing date of the Purchase Agreement, a right of participation of up to an aggregate of 35% in any subsequent offering of the Company, subject to certain exceptions.

 

The Warrants will be exercisable on a cashless basis in the event that, six months after the closing of the Purchase Agreement, there is not an effective registration statement for the resale of the shares underlying the Warrants. The Warrants may not be exercised to the extent such exercise would cause the holder to beneficially own more than 4.99% (or 9.99%, at the election of the investor) of the Company’s outstanding common stock.

 

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 8:-

SUBSEQUENT EVENTS (Cont.)

 

Pursuant to the Purchase Agreement, the Company agreed that it will not, for a period commencing upon the closing of the Purchase Agreement, until the earlier of (i) 150 days following the date that all of the common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale, (ii) six months after the date that a non-affiliate investor under the Purchase Agreement may first sell securities purchased thereunder under Rule 144, (iii) 120 days following the listing of the common stock on a Qualified Market (as defined below) and (iv) the first trading day that the weighted average price of the common stock exceeds $5.00 per share for 10 consecutive trading days occurring after the date that a registration statement covering the resale of all of the common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale, offer or sell any common stock (or securities convertible into or exercisable into common stock), or file any registration statement, other than pursuant to the Registration Rights Agreement or on Form S-8, subject to certain exceptions.

 

In connection with the Purchase Agreement, on October 22, 2018, the Company filed a Certificate of Designations of Series A Preferred Stock (the “Series A Certificate of Designations”) with the Secretary of State of Delaware. Pursuant to the Series A Certificate of Designations, the Company designated 1,350 shares of preferred stock as Series A Preferred Stock. The Series A Preferred Stock has a stated value of $1,000 per share and is convertible into shares of common stock in an amount determined by dividing the stated value of $1,000 by the conversion price of $1.00, such that each share of Series A Preferred Stock is convertible into 1,000 shares of common stock. The Series A Preferred Stock may not be converted into common stock to the extent such conversion would cause the holder to beneficially own more than 4.99% (or 9.99%, at the election of the investor) of the Company’s outstanding common stock. The Series A Preferred Stock is entitled to dividends on an as-converted basis with the common stock. The Series A Preferred Stock votes with the common stock on an as-converted basis, subject to the beneficial ownership limitation.

 

The Company will be obligated to pay liquidated damages to the investors if the Company fails to file the resale registration statement when required, fails to cause the Registration Statement to be declared effective by the SEC when required, fails to maintain the Registration Statement and upon the occurrence of certain other events. The Company shall pay to each investor cash equal to 2% of such investor’s total purchase price on the dates of each deficiency and on the 30^th day after such deficiencies until such deficiencies are cured, up to a maximum of 10% of the purchase price.  

 

The Company engaged ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”), as the placement agent for the private placement, pursuant to a placement agency agreement between the Company and ThinkEquity (the “Placement Agency Agreement”). The Company will pay ThinkEquity a fee equal to 8% of the gross proceeds, excluding proceeds received from certain investors for its services as placement agent, and will issue to ThinkEquity or its designees warrants to purchase 267,000 shares of common stock (equal to 6% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)).

  

 

WIZE PHARMA, INC. AND SUBSDIARIES

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

 

NOTE 8:-

SUBSEQUENT EVENTS (Cont.)

 

Such warrants will have an exercise price of $1.00 per share and will otherwise have the same terms as the Series A Warrants issued to the investors. The Company will also pay to ThinkEquity a non-accountable expense allowance of $30,000 and reimburse ThinkEquity for its legal expenses in connection with the offering in the amount of $50,000. The Company granted to ThinkEquity a right of first refusal for a period of nine months following the closing of the offering, to act as sole financial advisor, sole investment banker, sole book-runner, and/or sole placement agent, for each and every future public and private equity and debt offering of the Company during such period, on terms and conditions customary to ThinkEquity. The Company will also pay Mesodi Consultation & Investments, Ltd. (“Mesodi”) a fee of $89,000 and will issue to Mesodi warrants to purchase 89,000 shares of common stock. Such warrants will have the same terms as the Warrants issued to the investors, in connection with the private placement.

 

In connection with the Purchase Agreement, on October 19, 2018 the Company and its wholly-owned subsidiary Wize Pharma Ltd. (“Wize Israel”) entered into an amendment to the existing convertible loan (the “Amendment”). Pursuant to Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following the date that the registration statement the Company will file under the Registration Rights Agreement covering the resale of all common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale for investors who are not a party to the Loan Agreements Amendment, (b) 90 days following the date on which all securities issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement, and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the Amendment, the expiration date of the investment right under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan Agreements Maturity Date.

     

   

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets, statements of comprehensive loss and cash flows for the three and nine months ended September 30, 2018. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the SEC on March 29, 2018 and amended on June 5, 2018 (the “2017 Form 10-K”) and our accompanying unaudited interim consolidated financial statements and notes to these financial statements. All amounts are in U.S. dollars and rounded to thousands of U.S dollars, except for share and per share data.

 

Forward-Looking Statement Notice

 

This unaudited quarterly report on Form 10-Q contains forward-looking statements, about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the United States Securities and Exchange Commission, or the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our 2017 Form 10-K.

 

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements, particularly those set forth under Item 1A. “Risk Factors” as disclosed in our 2017 Form 10-K.

 

Such risk factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

 

Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

 

●

we have substantial debt which may adversely affect us by limiting future sources of financing, interfering with our ability to pay interest and principal on our indebtedness and subjecting us to additional risks;

 

●

we need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and will dilute current stockholders’ ownership interests;

 

●

our current pipeline is based on a single compound known as LO2A (“LO2A”) and on the continuation of our license to commercialize LO2A;

 

●

our inability to expand our rights under our LO2A License Agreement may have a detrimental effect on our business;

 

●

the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts;

 

●

our ability to advance our product candidate into clinical trials or to successfully complete our preclinical studies or clinical trials;

 

   

●

our receipt of regulatory approvals for our product candidate, and the timing of other regulatory filings and approvals;

 

●

the clinical development, commercialization and market acceptance of LO2A;

 

●

our ability to establish and maintain corporate collaborations;

 

●

the implementation of our business model and strategic plans for our business and product candidate;

 

●

the scope of protection we are able to establish and maintain for intellectual property rights covering LO2A and our ability to operate our business without infringing the intellectual property rights of others;

 

●

estimates of our expenses, future revenues, and capital requirements;

 

●

competitive companies, technologies and our industry; and

 

●

statements as to the impact of the political and security situation in Israel on our business.

 

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

 

Description of Business

 

On May 21, 2017, we entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”), with Bufiduck Ltd., a company formed under the laws of the State of Israel and our wholly owned subsidiary (“Merger Sub”) and Wize Israel, which contemplated the merger of Merger Sub with and into Wize Israel, with Wize Israel continuing as the surviving entity and becoming our wholly owned subsidiary (the “Merger”). On November 16, 2017, we were renamed “Wize Pharma, Inc.,” and completed our transaction with Wize Israel in accordance with the terms of the Merger Agreement pursuant to which Merger Sub merged with and into Wize Israel, with Wize Israel surviving as our wholly owned subsidiary. Prior to the Merger, we had no active business and were a “shell company” as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As a result of the Merger, we have ceased to be a “shell company” and the business of Wize Israel became our ongoing business.

 

Wize Israel was deemed to be the accounting acquirer in the Merger. Accordingly, the historical results of Wize Israel prior to the Merger are now presented as the historical results of the Company. 

 

We are a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (“DES”). We have in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including Conjunctivochalasis (“CCH”) and Sjögren’s syndrome (“Sjögren’s”).

 

LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH and in the Netherlands for the treatment of DES and Sjögren’s.

 

We intend to market LO2A as a treatment for DES and other ophthalmic inflammations, including CCH and Sjögren’s in the United States, Israel, Ukraine and the People’s Republic of China (“China”) in the territories that we have licensed LO2A, and in additional territories, subject to purchasing the rights to market, sell and distribute LO2A in those additional territories. We believe that the potential for the most economic success is in marketing LO2A for treating CCH and Sjögren’s. Currently, we have a distribution agreement for marketing in Israel, where LO2A is approved for the treatment of DES only, a distribution agreement for marketing in Ukraine, where the Company plans to register LO2A for the treatment of DES and CCH, and a distribution agreement for distribution in China, where the preparation for the registration process commenced in December 2017 by the Chinese distributor. The registration process in certain countries, including the United States, requires us to conduct additional clinical trials, in addition to the Phase II and Phase IV clinical trials that we are currently conducting.

 

   

We plan to engage local or multinational distributors to handle the distribution of LO2A. In particular, we intend to engage, subject to obtaining the requisite rights in LO2A, pharmaceutical companies or distributors around the world with relevant marketing capabilities in the pharmaceutical field, in order for such pharmaceutical companies to sell LO2A, with us prioritizing those territories where we may expedite the registration process of LO2A based on existing knowledge and studies previously conducted on LO2A, without requiring additional studies. In case additional studies are required and / or existing certification or documentation is required, the Company will re-evaluate the economic value and expected time frame to obtain said objective.

 

In August 2016, we commenced the Multi-Center Trial, which is a Phase II randomized, double-blind, placebo-controlled, clinical trial, in parallel groups which is intended for the repeated confirmation of the effectiveness and safety of LO2A for patients suffering from moderate to severe CCH. The trial is a multi-center trial in five different medical centers in Israel. All the 62 patients finished their three months treatment time. We believe that we currently have sufficient funds to complete the Multi-Center Trial, and expect results by the end of 2018.

 

In March 2018, we commenced a Phase IV Study. The Phase IV Study is a multi-center trial in three different medical centers in Israel and will evaluate the safety and efficacy of LO2A for symptomatic improvement of DES in 60 adult patients with Sjögren’s. Enrolled patients will be randomized in a 1:1 ratio to one of two treatment groups, LO2A or Systane^® Ultra UD. Drops will be administered topically to the eye over a three month period. This Phase IV Study is designed to support our clinical approval pathway for LO2A for the treatment of DES in patients with Sjögren’s within certain markets including the U.S., China, Ukraine and Israel.

 

We have not generated any revenues from operations since our inception, other than immaterial revenue in Israel during the third quarter of 2018 of $7,000 which were deducted from research and development expenses, we do not currently expect to generate any significant revenues for the foreseeable future, primarily because LO2A is still in early clinical stage development in the markets and for the indications we are currently targeting. Our operating expenses have increased from $1,048,000 in the nine months ended September 30, 2017 to $2,765,000 in the nine months ended September 30, 2018. We will require significant additional capital and, assuming we will have sufficient liquidity resources, we anticipate we will incur significantly higher costs in the foreseeable future, in order to finance our current strategic plans, including the conduct of ongoing and future clinical trials as well as further research and development. 

 

Results of Operations - Nine months Ended September 30, 2018 Compared to the Nine Months Ended September 30, 2017

 

		Nine Months Ended September 30,
		2018				2017
Operating expenses:
Research and development		$	(521,000	)			(288,000	)
General and administrative			(2,244,000	)			(760,000	)
Total operating costs			(2,765,000	)			(1,048,000	)
Financial income (expense), net			1,277,000				(1,016,000	)
Net loss		$	(1,488,000	)			(2,064,000	)

 

   

Revenues

 

We did not generate any material revenues from operations during the nine months ended September 30, 2018 and we did not generate any revenues from operations during the nine months ended September 30, 2017. We had no revenues primarily because (1) from the time of the Creditors’ Arrangement (as defined below) of Wize Israel in February 2015 until May 2015, when we (through Wize Israel) entered into the LO2A License Agreement, Wize Israel did not conduct any business operations and (2) thereafter, currently, Wize Israel is engaged primarily in research and development. Pursuant to the LO2A License Agreement, Wize Israel is required to pay Resdevco certain royalties for sales in the licensed territories based on an agreed-upon price per unit of either $0.60, in the United States, Israel and Ukraine, or in the low single digits of US Dollars, in the People’s Republic of China, payable on a semi-annual basis, subject to making certain minimum royalty payments as set forth in the LO2A License Agreement.

 

Operating Expenses

 

Research and development expenses. Research and development expenses were $521,000 for the nine months ended September 30, 2018, compared to $288,000 for the nine months ended September 30, 2017, an increase of $233,000 or 80.9 %. The increase in research and development expenses is primarily related to additional expenses related to clinical trials. In 2017 all research and development expenses related to CCH clinical trial, while in 2018 research and development expenses related both to CCH and Sjögren clinical trials.

 

General and administrative expenses. General and administrative expenses were $2,244,000 for the nine months ended September 30, 2018, compared to $760,000 for the nine months ended September 30, 2017, an increase of $1,484,000 or 195.3%. The increase in general and administrative expenses during these periods is primarily related to increases in investor’s relationship expense of $105,000, increase in professional and legal services of $89,000, increase in expenses related to issuance of RSU’s to Company’s officers and directors of $471,000 and other stock-based compensation expense of $649,000.

 

Financial Income (expense), Net. Financial income (expense), net was $1,277,000 for the nine months ended September 30, 2018 compared to financial expense, net of $(1,016,000) for the nine months ended September 30, 2017, a change of $2,293,000 or 225.7%. The decrease in financial expenses during this period is primarily related to the amortization of BCF, proceeds allocated to the derivative liability and debt issuance costs for convertible loans of $(729,000) during the nine months ended September 30, 2017 compared to no such expense in 2018, change in the fair value of derivative liability for Right to Future Investment of $(261,000) during the nine months ended September 30, 2017 compared to no such expense in 2018, and amortization of premium related to convertible loans of $1,338,000 which we did not have in the nine month period ended September 30, 2017.

 

Net Loss. As a result of the foregoing, we incurred a net loss of $1,488,000 for the nine months ended September 30, 2018 compared to a net loss of $2,064,000 for the nine months ended September 30, 2017, a decrease in the net loss of $576,000 or 27.9%.

 

Results of Operations -Three Months Ended September 30, 2018 Compared to the Three Months Ended September 30, 2017

 

		Three Months Ended September 30,
		2018				2017
Operating expenses:
Research and development		$	(222,000	)			(107,000	)
General and administrative			(738,000	)			(229,000	)
Total operating costs			(960,000	)			(336,000	)
Financial income (expense), net			445,000				(392,000	)
Net loss		$	(515,000	)			(728,000	)

 

   

Operating Expenses

 

Research and development expenses. Research and development expenses were $222,000 for the three months ended September 30, 2018, compared to $107,000 for the three months ended September 30, 2017, an increase of $115,000 or 107.4%. The increase in research and development expenses is primarily related to additional expenses related to clinical trials. In 2017 all research and development expenses related to CCH clinical trial, while in 2018 research and development expenses related both to CCH and Sjögren clinical trials.

 

General and administrative expenses. General and administrative expenses were $738,000 for the three months ended September 30, 2018, compared to $229,000 for the three months ended September 30, 2017, an increase of $509,000 or 222.2%. The increase in general and administrative expenses during these periods is primarily related to increases in professional and legal services and share-based compensation expense.

 

Financial Income (expense), Net. Financial income (expense), net was $445,000 for the three months ended September 30, 2018 compared to financial expense, net of $(392,000) for the three months ended September 30, 2017, a change of $837,000 or 218%. The decrease in financial expenses during this period is primarily related to the amortization of BCF, proceeds allocated to the derivative liability and debt issuance costs for convertible loans of $(368,000) (compared to no such expense in 2018) and amortization of premium related to convertible loans of $446,000 which we did not have in the three month period ended September 30, 2017.

 

Net Loss. As a result of the foregoing, we incurred a net loss of $515,000 for the three months ended September 30, 2018 compared to a net loss of $728,000 for the three months ended September 30, 2017, a decrease in the net loss of $213,000 or 29.1 %.

 

Liquidity and Capital Resources

 

General

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures. Since the court-approved Creditors Arrangement (as defined below) completed in February 2015, as described below, we financed our operations primarily through equity and convertible debt financings in private placements, as described below.

 

   

Working Capital and Cash Flows

 

As of September 30, 2018 and December 31, 2017, we had $99,000 and $215,000 in cash and cash equivalents, respectively.

 

As of September 30, 2018 and December 31, 2017, we had $1,906,000 and $3,204,000, respectively, of outstanding loans payable, including accrued interest and net of discounts (or premium), all of which relates to convertible loans, as described below. However, the aggregate principal amount of such loans is $1,353,000 (not including interest).

 

As of September 30, 2018 and December 31, 2017, we had $(2,202,000) and $(3,103,000) of working capital (deficit), respectively. As of September 30, 2018, we had an accumulated deficit of $27,914,000. The decrease in working capital deficit was primarily due to the exercise by Ridge Valley Corporation (“Ridge”), Rimon Gold Assets Ltd. (“Rimon Gold”), Shimshon Fisher (“Fisher”), Simcha Sadan (“Sadan”) of PIPE Warrants and Investment Rights as more fully described below and due to amortization of premium related to convertible loans.

 

The following table presents the major components of net cash flows (used in) provided by operating, investing and financing activities for the periods presented:

 

		Nine Months Ended September 30,
		2018				2017
Net cash used in operating activities		$	(1,378,000	)		$	(983,000	)
Net cash provided by (used in) investing activities		$	267,000			$	(2,000	)
Net cash provided by financing activities		$	995,000			$	1,511,000

 

Nine Months Ended September 30, 2018 Compared to Nine Months Ended September 30, 2017

 

For the nine months ended September 30, 2018 and 2017, net cash used in operating activities was $(1,378,000) and $(983,000), respectively. The increase in net cash used in operating activities was mainly due to a decrease in net loss of $576,000 and an increase in stock-based compensation of $1,212,000, which were mitigated by amortization of a premium related to convertible loans of $1,338,000.

 

For the nine months ended September 30, 2018 and 2017, net cash used in investing activities was $267,000 and $(2,000), respectively. The increase in net cash provided by investing activities was mainly due to proceeds from sale of marketable equity securities of $257,000 and from decrease in restricted bank deposit of $12,000.

 

For the nine months ended September 30, 2018 and 2017, net cash provided by financing activities was $995,000 and $1,511,000, respectively. Cash was provided in the nine months ended September 30, 2018 by proceeds of $995,000 that comprise of payment of license purchase obligation of $150,000 and $1,145,000 that were received from issuance of shares with respect to exercise of PIPE warrants and 2016 and 2017 right for future investment. On March 26, 2018, Rimon Gold exercised a portion of their 2016 Investment Right (as defined below) and received 217,442 shares of Common Stock in exchange for approximately $284,000. On March 26, 2018, Ridge exercised a portion of their 2017 Investment Right (as defined below) and received 213,524 shares of Common Stock in exchange for approximately $284,000. On March 26, 2018, Sadan exercised a portion of his warrants to purchase (as adjusted based on an exchange ratio of each ordinary share of Wize Israel issued and outstanding converted into 4.1445791236989 shares of the Company’s Common Stock (the “Exchange Ratio”)) an aggregate of 904,036 shares of our Common Stock at an exercise price of $1.9728 (the “PIPE Warrants”), which PIPE Warrants were granted on November 16, 2017 and was issued 144,168 shares of our Common Stock in exchange for approximately $293,000. On February 22, 2018, we received notices from certain lenders to exercise 2017 Investment Rights to purchase an aggregate of 213,524 shares of Common Stock for approximately $284,000. In April, May and July, 2018, the Company received the aggregate exercise price of approximately $284,000, and in July 2018 the Company issued 213,524 shares of Common stock related to the exercise notice mentioned above. Cash was provided in the nine month period ended September 30, 2017 primarily by proceeds from issuance of units consisting of ordinary shares and detachable warrants, net of issuance costs of $963,000 and proceeds from issuance of convertible loan, net of issuance costs of $620,000.

  

    

Outlook

 

According to management estimates, liquidity resources as of September 30, 2018 may not be sufficient to maintain our planned level of operations for the next 12 months. In particular, if needed, we may raise additional funding (in addition to the October 2018 Private Placement). However, for a long-term solution, we will need to seek additional capital for the purpose of implementing our business strategy and managing our business and developing drug candidates. Conducting clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic objectives. We have not yet generated any revenues from our current operations, and therefore we are dependent upon external sources for financing our operations. We will require significant additional financing in the near future. Additional financing may not be available on acceptable terms, if at all. Our future capital requirements as well as the ability to obtain financing will depend on many factors, including those listed under Item 1A - “RISK FACTORS – Risks Related to our Business,” in our 2017 Form 10-K. As of September 30, 2018, we had an accumulated deficit and a stockholders’ deficit. In addition, during the nine months ended September 30, 2018 and 2017, we reported losses and negative cash flows from operating activities. Our management considered the significance of such conditions in relation to our ability to meet our current and future obligations and determined that such conditions raise substantial doubt about each our ability to continue as a going concern.

     

We currently have no agreements, arrangements, or understandings with any person to obtain funds through bank loans, lines of credit, or any other sources. Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through debt or equity financings, or by out-licensing our distribution rights. We cannot be certain that additional funding will be available to us on acceptable terms, or at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our commercialization efforts.

  

We are addressing our liquidity issues by implementing initiatives to raise additional funds as well as other measures that we believe will allow us to continue as a going concern. Such initiatives may include monetizing of our assets, including the sale of the Can-Fite BioPharma Ltd. shares that we currently own that are presented as marketable equity securities in the accompanying unaudited interim consolidated financial statements.

 

Principal Financing Activities. The following is a summary of the equity and debt financings conducted by Wize Israel since the Creditors’ Arrangement (as defined below):

 

In December 2014, an Israeli court approved a creditors’ arrangement under the Israeli Companies Law between Wize Israel (then known as Star Night Technologies Ltd.), its creditors and its shareholders (the “Creditors’ Arrangement”), in which Wize Israel was purchased by a group of investors led by Ridge. Upon the completion of the Creditors’ Arrangement, all of Wize Israel’s assets, rights and obligations were transferred to the creditors’ arrangement fund, so that Wize Israel’s equity after the approval of such arrangement was zero and Wize Israel remained a public shell company without any activity, rights or obligations. The Creditors’ Arrangement was completed in February 2015. In connection with the Creditors’ Arrangement, on February 15, 2015, Wize Israel issued 692,307 ordinary shares of Wize Israel, in the aggregate, to Ridge, Yaakov Zarachia (“Zarachia”), Avner Arazi (“Arazi”) and Amir Bramli (“Bramli”, and together with Ridge, Zarachia and Arazi, the “2015 Investors”), in exchange for their purchase of the public shell for NIS 1,800,000 (approximately $463,000). In addition, on April 7, 2015, for no consideration, the 2015 Investors provided Wize Israel with a capital amount of NIS 4,056,000 (approximately $1,044,000) in cash.

 

As of September 30, 2018, we (through Wize Israel) had a total principal and accrued interest balance of approximately $1.4 million of loans outstanding under the convertible loans described below, of which (1) Ridge extended a principal amount of NIS 1.0 million (approximately $270,000), (2) Rimon Gold extended a principal amount of NIS 3.0 million (approximately $811,000), and (3) Fisher (not affiliated, to Wize Israel’s knowledge, with Ridge or Rimon Gold) extended a principal amount of NIS 1.0 million (approximately $270,000). Below is a summary of the material provisions of these loan agreements.

 

The 2016 Loan. On March 20, 2016, Wize Israel entered into a convertible loan (as amended on March 30, 2016, December 21, 2017 and October 19, 2018, the “2016 Loan Agreement”) with Rimon Gold, whereby Rimon Gold extended a loan in the principal amount of up to NIS 2 million (approximately $519,000), which bears interest at an annual rate of 4% (the “2016 Loan”). Pursuant to the 2016 Loan Agreement, as modified by the 2017 Loan Agreement (as defined below) and the 2017 Loan Amendment (as defined below), both described below, the 2016 Loan has a maturity date (the “New Loan Agreements Maturity Date”) that shall be the earliest of (a) 90 days following the effectiveness of the registration statement registering for resale the common stock, conversion shares and warrant shares issued in the Company’s October 2018 Private Placement (as described below) that are held by holders not parties to the 2017 Loan Amendment, (b) 90 days following the date on which all securities issued to investors in the October 2018 Private Placement are no longer deemed “registrable securities” under the registration rights agreement entered into in connection with the October 2018 Private Placement, and (c) one year following the closing of the October 2018 private placement. In addition, pursuant to the 2017 Loan Amendment, the expiration date of the investment right under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the New Loan Agreements Maturity Date.

   

Under the 2016 Loan Agreement, Rimon Gold had the right, at its sole discretion, to convert any outstanding portion of the 2016 Loan, but not less than NIS 100,000 (approximately $26,000), into Wize Israel ordinary shares at a conversion price per share of NIS 15.2592 (approximately $3.84), subject to adjustments for stock splits and similar events set forth in the 2016 Loan Agreement. As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016 Loan was adjusted to NIS 3.60 (approximately $0.96). As a result of the 2017 Loan Amendment (as defined below), the aggregate principal amount of the 2016 Loan is $531,067 and the conversion price per share for the 2016 Loan was adjusted to $0.9768.

 

In order to secure its obligations and performance pursuant to the 2016 Loan Agreement, Wize Israel recorded a first priority fixed charge in favor of Rimon Gold on all of Wize Israel’s rights, including its distribution rights, under the LO2A License Agreement, and a first priority floating charge on all of Wize Israel’s rights, title and interest in all of its assets, as they may exist from time to time (the agreements relating to such charges being referred to as the “Security Agreements”).

 

   

Rimon Gold is entitled, under certain circumstances, to demand repayment of the 2016 Loan, including among others: (i) if Wize Israel breaches or fails to perform or is shown to have made a false statement, under the 2016 Loan Agreement or the Security Agreements; (ii) any failure of Wize Israel to make a timely payment; (iii) upon the appointment of a receiver; (iv) the imposition of a lien on a material asset of Wize Israel; (v) if Wize Israel files a motion to stay proceedings; (vi) upon the expiration or termination of the LO2A License Agreement or if any party is in material breach of the LO2A License Agreement or if any party notifies the other of its intention to terminate the LO2A License Agreement; (vii) an adverse material change; and (viii) upon the non-performance of Wize Israel pursuant to the 2017 Loan Agreement (as defined below) described below. We believe that we have complied with the aforementioned covenants through September 30, 2018.

 

The 2016 Loan Agreement and the Security Agreements contain a number of other restrictive covenants that limit Wize Israel’s operating flexibility. These covenants include, among other things, limitations on the creation of liens; on the incurrence of indebtedness; on dispositions of assets, mergers, acquisitions and other change of control transactions; on changes in the general nature of Wize Israel’s business; restrictions on payments to related parties; restrictions on conducting rights offerings, and on the distribution of dividends. We believe that we have complied with the aforementioned covenants through September 30, 2018.

  

In addition, under the 2016 Loan Agreement, as modified by the 2017 Loan Agreement (as defined below) and the 2017 Loan Amendment (as defined below), Rimon Gold has the right, until June 30, 2019, to invest up to $796,601, in the aggregate, at an agreed price per share, which was adjusted based on the Exchange Ratio from NIS 20.4 (approximately $6.00) to NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment (as defined below), from NIS 5.04 to a fixed price of $1.308 (subject to adjustments in case of stock splits or similar events) (the “2016 Investment Right”). See “-December 2017 Loan Amendment” below.

 

The 2017 Loan. On January 15, 2017, Wize Israel entered into the 2017 Loan Agreement (as amended on December 21, 2017, and October 19, 2018 the “2017 Loan Agreement”) with Ridge, and, by way of entering into assignments and assumption agreements following such date, also with Rimon Gold and Fisher (together, the “2017 Lenders”), whereby each of the lenders extended a loan in the principal amount of up to NIS 1 million (approximately $283,000) and in the aggregate principal amount of up to NIS 3 million (approximately $850,000), which bears interest at an annual rate of 4% (the “2017 Loan”, and together with the 2016 Loan, the “Loans”)). Pursuant to the 2017 Loan Agreement and the 2017 Loan Amendment, the 2017 Loan has a maturity date which is the “New Loan Agreements Maturity Date. In addition, pursuant to the 2017 Loan Amendment, the expiration date of the investment right under the 2017 Loan Agreement was amended to be 180 days after the New Loan Agreements Maturity Date.

  

Under the 2017 Loan Agreement, each of the 2017 Lenders had the right, at its sole discretion, to convert any outstanding portion of the 2017 Loan, but no less than NIS 100,000 (approximately $28,000), that the lender provided to Wize Israel (each such portion converted, the into Wize Israel ordinary shares at a conversion price per share equal to the lower of (1) NIS 24 (approximately $6.72) and (2) the lowest price per share of Wize Israel in any offering made by Wize Israel following the date of the 2017 Loan Agreement and through the date of such requested conversion, subject to adjustments for stock splits and similar events set forth in the 2017 Loan Agreement (the “2017 Loan Conversion Price”). As a result of the 2017 PIPE (as defined below), the 2017 Loan Conversion Price for Rimon Gold, Fisher and Ridge was adjusted to NIS 16.80 (approximately $4.80), and as a result of the Merger, the 2017 Loan Conversion Price of NIS16.80 (approximately $4.80) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately $1.15). As a result of the 2017 Loan Amendment, the aggregate principal amount of the 2017 Loan is $822,144 and the 2017 Loan Conversion Price was adjusted to a fixed price of $1.1112. See “-December 2017 Loan Amendment” below.

 

In addition, under the 2017 Loan Agreement, as modified by the 2017 Loan Amendment, the 2017 Lenders had the right, until June 30, 2019, to invest up to $1,233,216, in the aggregate, at an agreed price per share equal to 120% of the applicable 2017 Loan Conversion Price, which was adjusted based on the 2017 Loan Amendment, to a fixed exercise price of $1.332 (subject to adjustments in case of stock splits or similar events) (the “2017 Investment Right” and, together with the 2016 Investment Right, the “Investment Rights”). See “-December 2017 Loan Amendment” below.

 

Ridge is entitled, under certain circumstances, to demand repayment of the 2017 Loan, including: (i) if Wize Israel breaches or fails to perform or is shown to have made a false statement, under the 2017 Agreement or the Security Agreements; (ii) any failure of Wize Israel to make a timely payment; (iii) upon the appointment of a receiver; (iv) the imposition of a lien on a material asset of Wize Israel; (v) if Wize Israel files a motion to freeze proceedings; and (vi) an adverse material change. We believe that we have complied with the aforementioned covenants through September 30, 2018.

 

   

The 2017 Loan contains a number of restrictive covenants that limit Wize Israel’s operating flexibility. These covenants include, among other things, limitations on the creation of liens; on the incurrence of indebtedness; on dispositions of assets, mergers, acquisitions and other change of control transactions; on changes in the general nature of Wize Israel’s business; restrictions on payments to related parties; and on the distribution of dividends. Wize Israel has complied with the aforementioned covenants through the date of this Quarterly Report.

 

It should be noted that, prior to entering into the 2017 Loan Agreement, Ridge provided the following three loans to Wize Israel, all of which bore interest at an annual rate equal to the interest rates of the Israeli government bonds: (1) NIS 250,000 was extended in November 2016, (2) NIS 300,000 was extended in December 2016 and (3) NIS 200,000 was extended in February 2017 (together, the “Ridge Interim Loans”). On March 30, 2017, after Ridge already provided NIS 250,000 under the 2017 Loan Agreement out of the NIS 1 million committed by Ridge thereunder, Ridge exercised its right to have the Ridge Interim Loans treated as a portion of the remaining NIS 1 million.

  

In addition, as part of the 2017 Loan Agreement, Wize Israel and the other lenders agreed that (1) the security interests made under the Security Agreements will also serve to secure the loans made by Rimon Gold under the 2017 Loan Agreement, and (2) Rimon Gold will have the right to be repaid the full 2016 Loan prior to any repayment of the 2017 Loan.

 

December 2017 Loan Amendment. On December 21, 2017, we entered into an amendment (the “2017 Loan Amendment”) to the 2016 Loan Agreement and the 2017 Loan Agreement. Pursuant to the 2017 Loan Amendment, (i) the maturity date of the Loans was extended from December 31, 2017 to December 31, 2018; (ii) the exercise period of the 2016 Investment Right was amended so that it shall expire on June 30, 2019; (iii) the exercise period of the 2017 Investment Right was amended so that it shall expire, without the need to first convert the 2017 Loan, on June 30, 2019; and (iv) the below terms of the Loans were amended to be denominated in U.S. dollars instead of NIS:

  

		2016 Loan				2017 Loan
Aggregate Principal Amount		$	531,067			$	822,144	*
Conversion Price Per Wize US Share		$	0.9768			$	1.1112
Aggregate Maximum Investment Right		$	796,601			$	1,233,216	**
Exercise Price of Investment Right		$	1.308			$	1.332

 

*	Principal loan amount of $274,048 for each of the three 2017 Lenders.
**	Maximum Investment Right of $411,072 for each of the three 2017 Lenders.

 

Rimon Gold and Ridge Consents to the Merger Agreement. In connection with the Merger Agreement, Wize Israel sought and obtained the written consents of Rimon Gold and Ridge to the transactions contemplated by the Merger Agreement. The consent provided by Rimon Gold provided that it is based upon, among other things, the following obligations: (1) following the closing of the Merger Agreement, we will assist Rimon Gold with its filing requirements, if any, with the SEC with respect to beneficial ownership and similar reports; and (2) at closing of the Merger Agreement, we will execute and deliver to Rimon Gold an Irrevocable Guaranty and Undertaking (the “Wize Guaranty”), which we executed and delivered to Rimon Gold.

 

Under the Wize Guaranty, we irrevocably guarantee Wize Israel’s obligations to Rimon Gold under certain convertible loans. In addition, the Wize Guaranty contains a number of restrictive covenants that limit our operating flexibility. These covenants include, among other things, limitations on the creation of liens; on the incurrence of indebtedness; on dispositions of assets, mergers, acquisitions and other change of control transactions; on changes in the general nature of our business; and on the distribution of dividends. Wize Israel has complied with the aforementioned covenants through the date of this Quarterly Report.

 

   

2017 PIPE. On June 23, 2017, Wize Israel entered into a Private Placement Agreement (the “2017 PIPE Agreements”) with each of Yosef Eliyahu Peretz (“Peretz”), Zarachia, Sadan and Jonathan Brian Rubini (“Rubini”, and together with Peretz, Zarachia and Sadan, the “2017 PIPE Investors”). Pursuant to the 2017 PIPE Agreements, the 2017 PIPE Investors invested a total of up to NIS 3.49 million (approximately $1 million) in exchange for a total of 207,739 ordinary shares of Wize Israel, at a price per share of NIS 16.8 (approximately $4.8), with Peretz investing NIS 490,000 (approximately $139,000) in exchange for the private placement of 29,167 ordinary shares of Wize Israel (the “Peretz Financing”) and each of Zarachia, Sadan and Rubini (the “Other Investors”) investing NIS 1 million (approximately $282,000) in exchange for the private placement of 59,524 ordinary shares of Wize Israel each (together, the “Other Financing”, and together with the Peretz Financing, the “2017 PIPE”). At the effective time of the Merger, the 207,739 ordinary shares of Wize Israel that were issued to the 2017 PIPE Investors as part of the 2017 PIPE were automatically cancelled and converted, based on the Exchange Ratio, into an aggregate of 860,987 shares of our Common Stock.   

 

Subject to the closing of the Merger, Wize Israel also undertook to cause us to grant PIPE Warrants to each of the 2017 PIPE Investors, with each PIPE Warrant being exercisable into one share of our Common Stock, with a term of three years from the date of grant. According to the 2017 PIPE Agreements, the number of PIPE Warrants and the exercise price thereof will reflect, prior to giving effect to an adjustment based on the Exchange Ratio, (i) 30,625 warrants to Peretz and (ii) 62,500 warrants to each of the Other Investors, each warrant exercisable into one ordinary share of Wize Israel, at an exercise price of NIS 28.8 per share (approximately $8.40). Based on the Exchange Ratio, Peretz was granted 126,928 PIPE Warrants and each of the Other Investors was granted 259,036 PIPE Warrants, each at an exercise price of $1.9728. Consistent with the foregoing, we executed and delivered the PIPE Warrants to the 2017 PIPE Investors on November 16, 2017.

 

On June 22, 2017, Ridge provided notice to Wize Israel that it had waived its right to adjust the 2017 Loan Conversion Price in connection with the Peretz Investment. On July 4, 2017, Wize Israel completed the Peretz Investment. However, Ridge did not waive its right to adjust the 2017 Loan Conversion Price in connection with the Other Investments. On July 31, 2017, at a general meeting of the shareholders of Wize Israel, the Other Investments was approved and on August 7, 2017 Wize Israel completed the Other Investments.

 

October 2018 Private Placement. On October 22, 2018, The Company entered into a securities purchase agreement (the “Purchase Agreement. Pursuant to the Purchase Agreement, the Company agreed to sell to the investors, and the investors agreed to purchase from the Company, in a private placement, an aggregate of (i) 3,100,000 shares of common stock, for a purchase price of $1.00 per share, and (ii) 1,350 shares of newly created Series A Preferred Stock (each convertible into 1,000 shares of common stock), for a purchase price of $1,000 per share, for aggregate gross proceeds under the Purchase Agreement of $4,450. The Company also agreed to issue to the investors Series A warrants (the “Series A Warrants”) to purchase an aggregate of 4,450,000 shares of common stock (equal to 100% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)), and Series B warrants (the “Series B Warrants, and together with the Series A Warrants, the “Warrants”), to purchase an aggregate of 4,450,000 shares of common stock (equal to 100% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)). The Series A Warrants will have an exercise price of $1.10 per share, and the Series B Warrants will have an exercise price of $1.00 per share. The investors under the Purchase Agreement include prior investors in the Company and a lender to the Company.

 

In connection with the Purchase Agreement, on October 19, 2018 the Company and its wholly-owned subsidiary Wize Pharma Ltd. (“Wize Israel”) entered into an amendment to the existing convertible loan (the “Amendment”). Pursuant to Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following the date that the registration statement the Company will file under the Registration Rights Agreement covering the resale of all common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale for investors who are not a party to the Loan Agreements Amendment, (b) 90 days following the date on which all securities issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement, and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the Amendment, the expiration date of the investment right under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan Agreements Maturity Date.

 

  

Off-Balance Sheet Arrangements

 

As of September 30, 2018 and December 31, 2017, we did not have any off-balance sheet arrangements, as such term is defined under Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

    

Recently Issued Accounting Pronouncements

 

For information with respect to recent accounting pronouncements, see Note 2w to our consolidated financial statements as of December 31, 2017 included in our 2017 Form 10-K and Note 2b to the accompanying Q3 2018 Financial Statements.

 

Critical Accounting Policies

 

Our critical accounting policies are described in the notes to our consolidated financial statements as of December 31, 2017 included in our 2017 Form 10-K.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a smaller reporting company, we have elected not to provide the disclosure required by this item.

 

Item 4. Controls and Procedures

 

Evaluation of disclosure controls and procedures

 

Our management, with the participation of our Acting Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)), as of the end of the period covered by this Quarterly Report. Based on such evaluation, our Acting Chief Executive Officer and Chief Financial Officer have concluded that As of September 30, 2018, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our Acting Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Changes in internal control over financial reporting

 

There has been no change in our internal control over financial reporting, as defined in Rule 13a-15(f) of the Exchange Act, during our most recent fiscal quarter ended September 30, 2018, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

   

PART II-OTHER INFORMATION

 

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds

   

In July 2018, the Company issued 67,778 shares of Common Stock to certain service providers in exchange for its services to be provided in 2018.

 

In August 2018, the Company issued to a consultant options to purchase 25,500 shares of Common Stock at an exercise price of $4.50 per share of Common stock. The options will vest quarterly over a period of 36 months.

 

On February 22, 2018, the Company received a notice from a certain lender to exercise a portion of its 2017 Investment Rights to purchase an aggregate of 213,524 shares of Common Stock at an exercise price per share of $1.332. In April, May and July 2018, the Company received an aggregate amount of $284,000, and in July 2018 issued 213,524 shares of Common stock.

 

We believe that all of the foregoing sales qualified for exemption under Section 4(a)(2) of the Securities Act since the issuance of the securities by us did not involve a public offering. The offerings were not “public offerings” as defined in Section 4(a)(2) due to the type of investors, the insubstantial number of investors involved in the offering, the size of the offering, the manner of the offering and number of securities offered. In addition, these security holders represented as to the necessary investment intent as required by Section 4(a)(2). Some of the foregoing sales were exempt from registration under Regulation D, and/or qualified as offshore transactions under Regulation S, each as promulgated under the Securities Act. We did not employ an underwriter in connection with the issuance of the securities described above.

 

Item 6. Exhibits

 

SEC Ref. No.		Title of Document
31.1		Rule 13a-14(a) Certification by Principal Executive Officer and Principal Financial and Accounting Officer*
32.1		Section 1350 Certification of Principal Executive Officer and Principal Financial and Accounting Officer*
101.INS		XBRL Instance Document **
101.SCH		XBRL Taxonomy Extension Schema Document **
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document **
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document **
101.LAB		XBRL Taxonomy Extension Label Linkbase Document **
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document **

 

*	Filed herewith
**	Attached as Exhibit 101 to this report are the following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Comprehensive Loss, (iii) the Consolidated Statements of Changes in Stockholders’ Deficit, (iv) the Consolidated Statements of Cash Flows, and (v) Notes to Q3 2018 Financial Statements.

 

   

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	Wize Pharma, Inc.
Date: November 13, 2018	By	/s/ Or Eisenberg
		Or Eisenberg
		Acting Chief Executive Officer,
		Chief Financial Officer, Treasurer and
		Secretary (Principal Executive Officer,
		Principal Financial and Accounting Officer)